Alnylam Pharmaceuticals (ALNY) : Opus Point Partners Management scooped up 27,371 additional shares in Alnylam Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 77,593 shares of Alnylam Pharmaceuticals which is valued at $4.1 Million.Alnylam Pharmaceuticals makes up approximately 3.87% of Opus Point Partners Management’s portfolio.
Other Hedge Funds, Including , Mizuho Asset Managementltd. sold out all of its stake in ALNY during the most recent quarter. The investment firm sold 816 shares of ALNY which is valued $42,881.Massachusetts Financial Services Co boosted its stake in ALNY in the latest quarter, The investment management firm added 985 additional shares and now holds a total of 79,978 shares of Alnylam Pharmaceuticals which is valued at $4.2 Million.Blackrock Institutional Trust Company N.a. boosted its stake in ALNY in the latest quarter, The investment management firm added 3,770 additional shares and now holds a total of 1,776,659 shares of Alnylam Pharmaceuticals which is valued at $93.4 Million. Alnylam Pharmaceuticals makes up approx 0.02% of Blackrock Institutional Trust Company N.a.’s portfolio. Penserra Capital Management added ALNY to its portfolio by purchasing 103 company shares during the most recent quarter which is valued at $5,413.Bronfman E.l. Rothschild reduced its stake in ALNY by selling 3 shares or 33.33% in the most recent quarter. The Hedge Fund company now holds 6 shares of ALNY which is valued at $333.
Alnylam Pharmaceuticals opened for trading at $58.23 and hit $64.64 on the upside on Wednesday, eventually ending the session at $63.55, with a gain of 9.93% or 5.74 points. The heightened volatility saw the trading volume jump to 20,10,631 shares. Company has a market cap of $5,437 M.
On the company’s financial health, Alnylam Pharmaceuticals reported $-1.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on May 2, 2016. Analyst had a consensus of $-1.09. The company had revenue of $7.35 million for the quarter, compared to analysts expectations of $7.74 million. The company’s revenue was down -60.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.62 EPS.
Many Wall Street Analysts have commented on Alnylam Pharmaceuticals. Chardan Capital Markets Initiated Alnylam Pharmaceuticals on Apr 5, 2016 to “Buy”, Price Target of the shares are set at $93.Alnylam Pharmaceuticals was Upgraded by JP Morgan to ” Overweight” on Mar 11, 2016. Shares were Reiterated by Leerink Partners on Feb 16, 2016 to “Outperform” and Lowered the Price Target to $ 120 from a previous price target of $152 .
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.